Clinical trial NCT00627419: A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic Melanoma
Official title: A Phase 2, Open-Label, Single-Arm, Multicenter Study Evaluating the Safety and Antitumor Activity of IPI-504, A Novel Small Molecule Inhibitor of Heat Shock Protein 90 (HSP90), in Patients With Metastatic Melanoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Metastatic Melanoma
Lead sponsor: Infinity Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2008-03-03
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To evaluate the antitumor activity of IPI-504 in patients with metastatic melanoma.

Detailed description: To evaluate the antitumor activity of IPI-504 in patients with metastatic melanoma and to assessment of antitumor activity is the 6-month progression-free rate.

Eligibility criteria: Inclusion Criteria:

* Histologically confirmed, unresectable, Stage IV or recurrent melanoma, including mucosal melanoma (based on American Joint Committee on Cancer \[AJCC\] staging \[Balch, 2001\], see Appendix A).
* Prior therapy with chemotherapy and/or immunotherapy for melanoma is allowed provided that therapy ended prior to study entry and all treatment-related toxicities have resolved to NCI CTCAE Grade ≤ 1 or patient's baseline;
* Measurable disease (based on RECIST \[Therasse, 2000\]) defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan;
* Have melanoma that can be biopsied once prior to treatment (all patients), and a second time during treatment with IPI504 (stage 2 patients);
* Willingness for tumor biopsy at screening (all patients) and once during treatment (stage 2 patients only);
* Males and females of at least 18 years of age at the time of study entry;
* Female patients must be of non child-bearing potential (defined as being \>1 year post-menopausal) or using effective contraception, eg, use of oral contraceptives with an additional barrier method (since the study drug may impair the effectiveness of oral contraceptives), double barrier methods (diaphragm with spermicidal gel or condoms with contraceptive foam), Depo-Provera, partner vasectomy, or total abstinence, from the time the informed consent is signed through 30 days after the last dose of IPI-504. Male patients must be surgically sterile or use a double-barrier method of contraception (condom with spermicide) from the time of the initiation of IPI-504 through 30 days after the last dose of IPI-504;
* Eastern Cooperative Oncology Group performance status of 0 to 2;
* Life expectancy of at least 16 weeks;
* White blood cell (WBC) count ≥ 3,000/mm3, absolute neutrophil count (ANC) ≥ 1,500/mm3, platelet count ≥ 100,000/mm3; Prothrombin time or international normalized ratio within normal range (unless a patient is receiving anticoagulation therapy), or PTT within normal range;
* Serum creatinine ≤ 1.5 × ULN and creatinine clearance ≥ 50 mL/min (by Cockroft-Gault method);
* Total bilirubin ≤ 1.5 × ULN \[unless due to Gilbert's syndrome (unconjugated hyperbilirubinemia) in which case the total bilirubin should be ≤ 3.5 mg/dL\], AST and ALT ≤ 2.5 × ULN, hepatic alkaline phosphatase ≤ 2.5× ULN;
* LDH ≤ 1.5 × ULN;
* Patients who have had prior radiation therapy are eligible provided that therapy was palliative in nature, not in the area where the tumor will be biopsied, at least one measurable lesion outside the radiation field, and all radiation-related toxicities have resolved to NCI CTCAE Grade ≤ 1 or patient's baseline;
* Patients who had recovered from prior major surgery are eligible if all surgical wounds have healed;
* Written informed consent and HIPAA authorization obtained from the patient prior to receipt of any study medication or beginning study procedures.

Exclusion Criteria:

* Received an investigational agent or therapy with any other kinase inhibitor within 2 weeks prior to study entry or any other antitumor therapy, such as cytostatic and/or cytotoxic drugs, hormonal therapy, radiation therapy, immunotherapy, or any biological response modifiers within 4 weeks prior to study entry;
* Previous treatment with 17-AAG, 17-dimethylaminoethylamino-17-demethoxygel-danamycin (17-DMAG), or other known Hsp90 inhibitor;
* Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for treatment of cancer;
* Current or planned participation (from the day of study entry through 30 days after the last dose of IPI-504) in a research protocol in which an investigational agent or therapy may be administered;
* Initiation or discontinuation of concurrent medication that alters CYP3A activity (see Appendix C) within 2 weeks prior to treatment with IPI-504. Patients who are on a stable dose of drugs known to alter CYP3A activity for \> 2 weeks are eligible to enroll;
* Presence of active infection or systemic use of antimicrobials within 72 hours prior to treatment with IPI-504;
* Known brain metastases or primary brain tumors. Patients with ≤ 2 lesions are eligible provided:

  * Treated with surgery or stereotactic radiosurgery
  * The lesions are \< 3 cm in size and have been stable for 2 months (by CT/MRI)
  * The patient has been off steroids for at least 1 week prior to dosing and:
  * The patient is allowed to have had whole brain radiation if performed in conjunction with surgery/stereotactic radiotherapy and the last dose of radiation occurred at least 2 months prior to dosing with IPI504.
* Significant comorbid condition or disease which in the judgment of the Investigator would place the patient at undue risk or interfere with the study (eg, cardiac disease such as acute coronary syndrome or unstable angina within 6 months, uncontrolled hypertension, cirrhotic liver disease, cerebrovascular accident, or other conditions);
* History of prior malignancies within the past 5 years other than non-melanomatous skin cancers that have been controlled, carcinoma in situ of the cervix, T1a or b prostate cancer noted incidentally during a transurethral resection of prostate (TURP) with prostate-specific antigen values within normal limits since TURP, or superficial bladder cancer;
* Women who are pregnant or lactating;
* Sinus bradycardia (resting heart rate \< 50 beats/min) secondary to intrinsic conduction system disease; Patients with sinus bradycardia secondary to pharmacologic treatment may enroll if withdrawal of the treatment results in normalization of the resting heart rate to within normal limits;
* Screening QTc \> 450 msec in males; QTc \> 470 msec in females, or previous history of QTc prolongation while taking other medications; or
* Active or recent history (within 3 months) of keratitis or keratoconjunctivitis, confirmed by ophthalmology or optometry exam.

Primary outcomes:
measure: Evaluating the antitumor activity of IPI-504 in patients with metastatic melanoma. The primary assessment of antitumor activity is the 6-month progression-free rate.
timeFrame: from the first administration of IPI-504 through 30 days after the last dose of IPI-504
Secondary outcomes:
measure: Evaluating other antitumor activities, safety, and PK parameters of IPI-504 in this patient population.
timeFrame: from the first administration of IPI-504 through 30 days after the last dose of IPI-504 (confirm)
Other outcomes:
Locations:
city: Tuscon
country: United States
facility: Arizona Cancer Center
state: Arizona
city: Los Angeles
country: United States
facility: The Angeles Clinic and Research Institute
state: California
city: San Diego
country: United States
facility: Sharp Memorial Hospital
state: California
city: Aurora
country: United States
facility: University of Colorado Health Sciences Center
state: Colorado
city: Miami
country: United States
facility: University of Miami - Sylvester Comprehensive Cancer Center
state: Florida
city: Atlanta
country: United States
facility: Winship Cancer Institute of Emory University
state: Georgia
city: Indianapolis
country: United States
facility: Indiana Univ. Melvin and Bren Simon Cancer Center
state: Indiana
city: Kansas City
country: United States
facility: University of Kansas Cancer Center
state: Kansas
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
city: Rochester
country: United States
facility: Mayo Comprehensive Cancer Center
state: Minnesota
city: St. Louis
country: United States
facility: Washington School of Medicine
state: Missouri
city: Lebanon
country: United States
facility: Dartmouth-Hitchcock Medical Center
state: New Hampshire
city: New York
country: United States
facility: Columbia University
state: New York
city: Canton
country: United States
facility: Gabrail Cancer Center
state: Ohio
city: Pittsburgh
country: United States
facility: Univ. of Pittsburgh Cancer Institute
state: Pennsylvania
city: Nashville
country: United States
facility: Vanderbilt Ingram Cancer Center
state: Tennessee
city: Houston
country: United States
facility: Univ. of TX, MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: Infinity Pharmaceuticals, Inc.
name: Pedro Santabarbara, M.D.
role: STUDY_DIRECTOR
References: